Previous Close | 0.9623 |
Open | 0.9623 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 0.9623 - 0.9623 |
52 Week Range | 0.9623 - 3.1900 |
Volume | |
Avg. Volume | 179 |
Market Cap | 43.724M |
Beta (5Y Monthly) | 1.40 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Vancouver, British Columbia--(Newsfile Corp. - April 23, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce that its second-generation ARMTM anti-cancer vaccine using AccuTOX®, called ARM-002TM, is therapeutically effective against pre-established melanoma when combined with the anti-PD-1 immune-checkpoint inhi
Vancouver, British Columbia--(Newsfile Corp. - April 17, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce that FMS Consult GmbH ("FMS"), a European corporate financing consulting firm, was commissioned by Defence to execute on a financing strategy for the Company. "Defence's successful technology development
Vancouver, British Columbia--(Newsfile Corp. - April 5, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in the field of immune-oncology, announces an amendment to the terms of 1,497,780 Class A Common share purchase warrants (the "Warrants") originally issued as part of a private placement closed on November 16, 2022. The expiry date will be extended by 12 months and ...